CLINICAL TRIALS PROFILE FOR CHLORPROPAMIDE

All Clinical Trials for CHLORPROPAMIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004363 ↗	Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus	Completed	Northwestern University		1995-12-01	OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004363 ↗	Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus	Completed	National Center for Research Resources (NCRR)		1995-12-01	OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00881543 ↗	"Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients"	Completed	University of Sao Paulo	N/A	2009-06-01	The purpose of this study is to demonstrate the secretion of glucose, insulin, glucagon, C-peptide and lipid profile after isocaloric diets with different nutritional compounds (fat, protein and carbohydrate food) in drug näive tipo 2 patients.
NCT00881543 ↗	"Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients"	Completed	University of Sao Paulo General Hospital	N/A	2009-06-01	The purpose of this study is to demonstrate the secretion of glucose, insulin, glucagon, C-peptide and lipid profile after isocaloric diets with different nutritional compounds (fat, protein and carbohydrate food) in drug näive tipo 2 patients.
NCT02456428 ↗	Incretin-based Drugs and the Risk of Heart Failure	Completed	Canadian Institutes of Health Research (CIHR)		2014-03-01	The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure (HF) compared to other combinations of oral hypoglycemic agents (OHA). The investigators will carry out separate population based cohort studies using administrative health databases in six jurisdictions in Canada, the US and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for HF. Analyses will be done separately for groups of patients with and without prior HF. The results from the separate sites will be combined to provide an overall assessment of the risk of HF in users of incretin-based drugs and by class of incretin-based drugs.
NCT02456428 ↗	Incretin-based Drugs and the Risk of Heart Failure	Completed	Drug Safety and Effectiveness Network, Canada		2014-03-01	The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure (HF) compared to other combinations of oral hypoglycemic agents (OHA). The investigators will carry out separate population based cohort studies using administrative health databases in six jurisdictions in Canada, the US and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for HF. Analyses will be done separately for groups of patients with and without prior HF. The results from the separate sites will be combined to provide an overall assessment of the risk of HF in users of incretin-based drugs and by class of incretin-based drugs.
NCT02456428 ↗	Incretin-based Drugs and the Risk of Heart Failure	Completed	Canadian Network for Observational Drug Effect Studies, CNODES		2014-03-01	The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure (HF) compared to other combinations of oral hypoglycemic agents (OHA). The investigators will carry out separate population based cohort studies using administrative health databases in six jurisdictions in Canada, the US and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for HF. Analyses will be done separately for groups of patients with and without prior HF. The results from the separate sites will be combined to provide an overall assessment of the risk of HF in users of incretin-based drugs and by class of incretin-based drugs.

Clinical Trial Conditions for CHLORPROPAMIDE

Condition Name

Condition Name for CHLORPROPAMIDE
Intervention	Trials
Diabetes Mellitus, Type 2	2
Diabetes Type 2	1
Type 2 Diabetes Mellitus	1
Diabetes Insipidus	1

Condition MeSH

Condition MeSH for CHLORPROPAMIDE
Intervention	Trials
Diabetes Mellitus, Type 2	4
Diabetes Mellitus	4
Diabetes Insipidus, Neurogenic	1
Diabetes Insipidus	1

Clinical Trial Locations for CHLORPROPAMIDE

Trials by Country

Trials by Country for CHLORPROPAMIDE
Location	Trials
Canada	3
Brazil	1
United States	1

Trials by US State

Trials by US State for CHLORPROPAMIDE
Location	Trials
Illinois	1

Clinical Trial Progress for CHLORPROPAMIDE

Clinical Trial Phase

Clinical Trial Phase for CHLORPROPAMIDE
Clinical Trial Phase	Trials
N/A	1

Clinical Trial Status

Clinical Trial Status for CHLORPROPAMIDE
Clinical Trial Phase	Trials
Completed	5

Clinical Trial Sponsors for CHLORPROPAMIDE

Sponsor Name

Sponsor Name for CHLORPROPAMIDE
Sponsor	Trials
Canadian Network for Observational Drug Effect Studies, CNODES	3
Canadian Institutes of Health Research (CIHR)	3
Drug Safety and Effectiveness Network, Canada	3

Sponsor Type

Sponsor Type for CHLORPROPAMIDE
Sponsor	Trials
Other	12
NIH	1

CHLORPROPAMIDE Market Analysis and Financial Projection

Last updated: April 27, 2026

Chlorpropamide: Clinical Trials Update, Market Read-Out, and Projection

What is chlorpropamide’s current clinical-trials status?

Chlorpropamide (first-generation sulfonylurea) is an established older diabetes drug. Public registries show a pattern typical for off-patent legacy small molecules: limited sponsor-funded, prospective Phase 2 to Phase 4 development activity in recent years, with most activity historically shifting to trials focused on label maintenance, comparative effectiveness, pharmacovigilance, or small investigator-led studies rather than late-stage pivotal programs.

Clinical-trials update (registries and typical activity pattern)

• Late-stage (Phase 3/4) prospective development: Sparse for the drug as a stand-alone program in recent years, consistent with absence of modern, IP-driven lifecycle investments.
• Earlier-phase (Phase 1/2): Limited presence; when present, studies are usually academic or short and focus on pharmacokinetics, comparative glycemic control, or regimen substitutions.
• Interventional trials vs. observational studies: Observational studies and registry-type data pulls dominate over new randomized registration trials.

Implication for R&D decision-making

• Chlorpropamide does not show a footprint consistent with a currently funded path toward new regulatory approvals in major jurisdictions.
• The drug is best modeled as a value-based, generics-centered asset rather than a development-led pipeline.

How large is the chlorpropamide market today?

Chlorpropamide’s market is constrained by:

• Aging profile and declining clinician use versus newer sulfonylureas (and non-sulfonylurea options) due to tolerability and hypoglycemia risk tradeoffs.
• Geographic fragmentation of availability, with supply and uptake driven by local formularies, reimbursement, and generic penetration.
• IP obsolescence: chlorpropamide is not an IP-origin, premium-priced product; it is generally priced at generic levels.

Market sizing approach (what drives the number) Because chlorpropamide is widely generic and sold as an older, low-cost therapy, total market value is driven more by:

• Net unit volumes (how many patients still receive it)
• Local price levels (low, but varying by country and tendering)
• Formulary inclusion (hospital and primary care prescribing policies)

Market reality for legacy sulfonylureas

• In mature markets, chlorpropamide tends to represent a small slice of total oral diabetes spend and a smaller share of sulfonylurea volume compared with glimepiride, gliclazide, and glibenclamide, depending on the country.

Practical market conclusion

• The economic story is volume and tender access, not premium pricing.
• For investment screens, chlorpropamide behaves like a low-growth, supply-sensitive generics product, unless a specific geography shows unusual formulary dependence.

Where does chlorpropamide fit in treatment pathways?

Chlorpropamide is a sulfonylurea used for type 2 diabetes. Its modern clinical niche is typically shaped by:

• Use where older sulfonylureas remain cost-preferred
• Patient-specific circumstances and physician familiarity
• Local reimbursement rules and product availability

Competitive set

• Newer sulfonylureas in many markets: gliclazide, glimepiride
• Alternative oral classes: DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists (for injectable but often part of pathway decisions)
• Insulin intensification when control fails

What do price and reimbursement dynamics imply for projections?

For generics, projection must treat value growth as primarily a function of:

• Volume (patient adherence, prescriber preference, switching patterns)
• Price erosion (tender and competitive generic pressure)
• Access risk (supply continuity and manufacturing compliance)

Directional outlook (next 3 to 7 years)

• Units: Slight to moderate decline likely in many formularies due to clinician preference for better-tolerated options, unless reimbursement systems keep older sulfonylureas entrenched.
• Value: Low single-digit growth or flat, with downside from ongoing price erosion and substitution to newer agents.
• Range-bound scenario: In countries with strong cost-control and established generic procurement, the value may remain stable even as clinical preference shifts.

Is there any modernization angle (new indications or formulation strategies)?

The drug’s development economics are usually defined by:

• New fixed-dose combinations
• Extended-release or improved safety formulations (rare for older molecules)
• Observational real-world studies for safety and effectiveness

Public-facing modernization is generally limited for chlorpropamide compared with newer antidiabetics that attract sponsor-led IP strategies.

Market projection framework for chlorpropamide

Because chlorpropamide is off-patent and sold generically, the most decision-relevant projection is scenario-based rather than a single-point forecast.

Scenario set for value (not IP premium) Assume the market evolves under four forces: prescribing trend away from first-generation sulfonylureas, generic price pressure, regional formulary inclusion, and competitive substitution within sulfonylureas and other oral agents.

3-year projection

• Base case: Low-to-flat value growth, modest unit decline offset by stable supply and pricing pockets.
• Downside case: Faster unit decline from substitution plus tender-driven pricing compression.
• Upside case: Continued formulary anchoring in specific geographies, with stable patient retention and supply.

5-year projection

• Base case: Gradual decline in units; value remains volatile and often flat-to-down depending on tender intensity and competitor share shifts.
• Downside case: Sustained substitution to glimepiride/gliclazide and newer classes; value declines more quickly.
• Upside case: Limited substitution due to cost dynamics, plus steady procurement cycles.

Competitive landscape: what impacts chlorpropamide’s share?

• Within-sulfonylurea substitution: Many prescribers prefer second-generation sulfonylureas for tolerability profiles.
• Non-sulfonylurea shift: SGLT2 inhibitors and DPP-4 inhibitors expand the menu with different hypoglycemia risk profiles.
• Patient selection: Older agents may persist where monitoring and cost constraints dominate.

Clinical development and regulatory positioning

Chlorpropamide is not a typical candidate for new registration trials unless a sponsor sees:

• A regulator-driven need for label expansion
• A combination strategy that changes clinical endpoints
• A safety-driven post-approval study mandate

For a legacy generic, the development activity pattern typically results in:

• Minimal or no high-cost pivotal trials
• More focus on quality, bioequivalence, and manufacturing compliance (for generic entrants)

Key data points for business diligence

Dimension	What matters for chlorpropamide	Business impact
Clinical pipeline	Limited sponsor-led late-stage development activity	Lower likelihood of new regulatory upside
Market structure	Generic, low-cost, tender- and formulary-driven	Value growth constrained by price erosion
Competition	Second-generation sulfonylureas and newer oral classes	Ongoing substitution risk
Forecast method	Scenario-based using unit trends and price erosion	Prevents overfitting to a single assumption
Investment lens	Supply continuity and local access	Manufacturing and procurement can matter more than R&D

Key Takeaways

• Chlorpropamide’s clinical-trials footprint is consistent with a legacy, off-patent sulfonylurea and lacks a visible pathway of sponsor-led late-stage development.
• The market is structurally constrained by generic pricing, ongoing substitution toward other diabetes therapies, and formulary dynamics that vary by geography.
• Projections should be scenario-based: a base case usually implies flat-to-down value with modest unit erosion; downside accelerates substitution and price compression; upside requires formulary anchoring in specific markets.

---

FAQs

1) Is chlorpropamide expected to gain a new indication soon?

No clear sign of sponsor-led, late-stage development that would typically precede meaningful label expansion for chlorpropamide in major jurisdictions.

2) What is the main driver of chlorpropamide revenue growth in the generic setting?

Unit volume retention and local price stability under tender and formulary rules.

3) How does chlorpropamide compete against newer diabetes drugs?

Mainly on cost and historical prescribing patterns; substitution pressure comes from second-generation sulfonylureas and newer non-sulfonylurea options.

4) Is clinical trial activity more likely interventional or observational for legacy chlorpropamide?

Observational and non-pivotal studies are generally more common for legacy generics than new registration-grade interventional trials.

5) What’s the best investment thesis lens for chlorpropamide?

Supply and access economics (manufacturing reliability, regulatory compliance, and procurement fit) rather than R&D-driven market creation.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. Search results for chlorpropamide (accessed 2026-04-27).
[2] FDA (Drugs@FDA). Chlorpropamide product and labeling records (accessed 2026-04-27).
[3] EMA. European public assessment and medicine information for chlorpropamide (accessed 2026-04-27).
[4] International Diabetes Federation. Diabetes prevalence and treatment context by region (accessed 2026-04-27).